01995nas a2200325   4500000000100000008004100001260001300042653001200055653002400067653001600091653002300107653001100130653001200141653002200153653000900175653002300184653002500207653001800232653002400250100001200274700001300286700001500299700001300314245016400327856007300491300001300564490000700577520107100584022001401655       2009                            d  c2009 Oct10aAnimals10aAntigens, Bacterial10aBCG Vaccine10aBacterial Vaccines10aHumans10aleprosy10aMembrane Proteins10aMice10aMice, Inbred C57BL10aMycobacterium leprae10aT-Lymphocytes10aVaccines, Synthetic1 aMaeda Y1 aTamura T1 aMatsuoka M1 aMakino M00aInhibition of the multiplication of Mycobacterium leprae by vaccination with a recombinant M. bovis BCG strain that secretes major membrane protein II in mice.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756850/pdf/0203-09.pdf  a1399-4040 v163 a<p>The ability of a recombinant Mycobacterium bovis BCG strain that secretes major membrane protein II (MMP-II) of Mycobacterium leprae (BCG-SM) to confer protection against leprosy was evaluated by use of a mouse footpad model. C57BL/6J mice intradermally inoculated with BCG-SM produced splenic T cells which secreted significant amounts of gamma interferon (IFN-gamma) in response to either the recombinant MMP-II, the M. leprae-derived membrane fraction, or the BCG-derived cytosolic fraction in vitro more efficiently than those from the mice infected with the vector control BCG strain (BCG-pMV, a BCG strain containing pMV-261). A higher percentage of CD8(+) T cells obtained from BCG-SM-inoculated mice than those obtained from BCG-pMV-inoculated mice produced intracellular IFN-gamma on restimulation with the M. leprae antigens. BCG-SM inhibited the multiplication of M. leprae in the footpads of C57BL/6J mice more efficiently than BCG-pMV. These results indicate that a BCG strain that secretes MMP-II could be a better vaccine candidate for leprosy.</p>  a1556-679X